Financial Performance - Lantheus reported first quarter 2025 revenues of $3728 million, a 08% increase compared to $369975 million in the first quarter of 2024[62, 78] - Adjusted EPS for the first quarter of 2025 was $153, a 95% decrease compared to $169 in the first quarter of 2024[17, 79] - The company's net income for 1Q 2025 was $72945 million, a 443% decrease compared to $131066 million for 1Q 2024[78] Strategic Initiatives - Lantheus is integrating Evergreen Theragnostics Inc and planning to acquire Life Molecular Imaging Ltd to strengthen radiodiagnostic and therapeutic capabilities[17, 24] - The company is divesting its SPECT business to SHINE Technologies, LLC, with the transaction expected to close by the end of 2025[17, 24] - Lantheus has a strong cash position with $9385 million in cash on hand and $750 million available in revolving credit[17, 66] Product Performance and Market Outlook - PYLARIFY net sales were $2577 million in 1Q 2025, representing a 05% decrease compared to 1Q 2024[37, 62] - DEFINITY net sales were $792 million in 1Q 2025, a 35% increase year-over-year[47, 62] - The PSMA PET market may exceed $35 billion by the end of the decade, with an annual scan potential of approximately 750,000[40, 41]

Investor Presentation Q1 2025 SPEAKERS: McKeel Hagerty | Chief Executive Officer and Chairman Patrick McClymont | Chief Financial Officer FORWARD LOOKING STATEMENTS / NON-GAAP FINANCIAL MEASURES This presentation contains statements that constitute "forward-looking statements" within the meaning of the federal securities laws. All statements we provide, other than statements of historical fact, are forward-looking statements, including those regarding our future operating results and financial position, our ...

Financial Performance - Net revenue increased by 8.9% on a constant-currency basis and 10.4% organically[15] - Cardiopulmonary revenue grew by 15.0%, driven by Essenz™ Perfusion system sales and consumables demand[12] - Neuromodulation revenue increased by 4.7%, with strength in Europe and Rest of World regions[12] - U S Epilepsy revenue grew 2.2%, partially impacted by procedure deferrals[12] - Adjusted diluted EPS was $0.88[12] - Adjusted free cash flow was $20 million[12] Guidance and Outlook - Full-year 2025 revenue guidance raised by 100 basis points to 6.0% - 7.0% on a constant-currency basis and 7.0% - 8.0% on an organic basis[10] - Full-year 2025 adjusted diluted earnings per share range revised to $3.60 - $3.70[10] - Adjusted operating income margin increase of > 190bps and adjusted operating income growth of > 15% is expected[45] - Targeting $135 - $155 million of adjusted free cash flow for full-year 2025[39] SNIA Environmental Liability - Recorded a liability of €333.3 million ($360.4 million as of March 31, 2025) related to SNIA environmental liability ruling[10]

Q 1 2 0 2 5 E A R N I NG S P R E S E N TAT I O N M A Y 2 0 2 5 Disclaimer Forward-Looking Statements and Non-GAAP Financial Measures This presentation includes certain financial measures that have not been prepared in a manner that complies with generally accepted accounting principles in the United States ("GAAP"), including, without limitation, EBITDA, Station Operating Income ("SOI", and "SOI Margin") (collectively, the "non-GAAP financial measures"). These non-GAAP financial measures are not measures of ...

Financial Performance & Strategy - The company maintained a strong balance sheet with a net leverage ratio of 1.5x[6,57] - The company generated $6 million in free cash flow in 1Q25[6,66], improving on historical quarterly seasonality[66] - The company is executing on an initial $100 million share repurchase authorization, with $8 million repurchased in March, representing approximately 185,000 shares[6] - The company is targeting $190 million - $210 million of free cash flow in 2025[52], with a 40%+ free cash flow conversion rate[50] - The company anticipates ~$70 million in annual interest expense savings due to debt refinancing completed in December 2024[55,57] Revenue & Growth - New orders increased by 36% year-over-year, boosting the product backlog[6,28] - The company's total revenue for 1Q25 was $841.1 million [71], down 3.5% year-over-year excluding FX impacts[23,28] - The company anticipates revenue to be weighted towards the back-half of the year with a 45% 1H / 55% 2H split[50] Banking & Retail Segments - Banking revenue for 1Q25 was $629.5 million [85], flat year-over-year in constant currency[36] - Retail revenue for 1Q25 was $211.6 million [85], down 12.4% year-over-year in constant currency[42] Cost Management & Tariffs - The company estimates the gross cost impact of current tariff policies to be approximately $20 million [46,49], with mitigation strategies expected to offset up to approximately 50% of the gross cost increase in 2025[49]

Financial Performance (Q1 2025) - Revenues reached $604647 thousand, slightly decreasing from $605672 thousand in Q1 2024[16] - Net income attributable to The GEO Group, Inc was $19558 thousand, down from $22668 thousand in Q1 2024[16] - Adjusted EBITDA was $99765 thousand, compared to $117643 thousand in Q1 2024[17] - Net Operating Income (NOI) totaled $155578 thousand, a decrease from $169060 thousand in Q1 2024[19] Guidance for 2025 - Revenue is projected to be between $2500000 thousand and $2550000 thousand[13] - Net income attributable to GEO is expected to range from $108000 thousand to $125000 thousand[13] - Adjusted EBITDA is forecasted to be between $465000 thousand and $490000 thousand[13] - Capital expenditures are estimated at $120000 thousand to $135000 thousand, including growth, technology, and facility maintenance[13] Operational Data (Q1 2025) - The company's worldwide operations include 98 facilities with approximately 77000 beds[7] - Owned and Leased Secure Services had 35455 revenue producing beds with 85% occupancy[21] - Managed Only facilities had 21919 revenue producing beds with 96% occupancy[21] - The contract retention rate for Owned & Leased facilities was 935%[28]

Financial Performance - Adjusted EBITDA, excluding catastrophes, grew by 14% to $439 million in Q1 2025 compared to $384 million in Q1 2024[11, 46] - Adjusted EPS, excluding catastrophes, increased by 16% to $579 per share in Q1 2025 from $497 per share in Q1 2024[11, 48] - The company reaffirmed its 2025 enterprise outlook, projecting modest growth in both Adjusted EBITDA and Adjusted EPS, excluding catastrophes[13] Segment Performance - Global Housing Adjusted EBITDA, excluding catastrophes, increased by 31% to $269 million in Q1 2025 from $205 million in Q1 2024[24, 60] - Global Housing combined ratio, including catastrophes, was 94% in Q1 2025[26] - Global Lifestyle Adjusted EBITDA decreased by 5% to $198 million in Q1 2025 from $208 million in Q1 2024[20] Capital Management - The company generated $67 million in cash during the quarter[11] - $103 million was returned to shareholders through share repurchases and common stock dividends[11] - Share repurchases totaled $62 million in Q1 2025, with an additional $25 million repurchased between April 1 and May 2[49] Catastrophe Reinsurance - The U S program provides approximately $18 billion of coverage in excess of a $160 million retention[66] - The total program coverage protects against a projected probable maximum loss of approximately a 1-in-265-year storm[66]

FIRST QUARTER 2025 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934. These statements include, but are not limited to, statements contained under "Fiscal 2025 Outlook," as well as other statements related to our current beliefs and expectations regarding the performance of our industry, the Company's strategic direction, mar ...

COTY 3Q FY25 EARNINGS CALL May 6, 2025 CURRENT BACKDROP SUE NABI CHIEF EXECUTIVE OFFICER CHALLENGES FROM SLOWER CATEGORY TRENDS, ELEVATED PRESTIGE COMPARISONS AND RETAILER DESTOCKING, AND RECALIBRATED CB EQUATION COTY FOCUSED ON PROTECTING PROFITABILITY, CASH FLOW AND DELEVERAGING PATH COTY MORE STRONGLY POSITIONED TO WEATHER CURRENT TARIFF AND MACRO UNCERTAINTY 2 3 Q3 SALES -2.5% WITH LFL VOLUMES -3%, INCLUDING FRAGRANCES +1% -4.8% PRESTIGE CONSUMER BEAUTY WITH VOLUMES FLAT Notes: All figures refer to LFL ...

Valens Semiconductor (NYSE:VLN) May 2025 1 Forward-Looking Statements Certain statements in this presentation (this "Presentation") are "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predi ...